ANN ARBOR, Mich., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report fourth quarter and full year 2025 financial results before the market opens on Tuesday, March 10, 2026. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours ...

CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that management will be participating in the upcoming investor conferences: TD Cowen 46th Annual Health Care ConferenceDate: Tuesday, March 3, 2026Fireside Chat Time: 1:10 p.m. ETLocation: Boston, MA Leerink Global Healthcare ConferenceDate: Monday, March 9, 2026Fireside Chat Time: 8:40 a ...

Baker Hughes to provide 25 BRUSH™ Power Generation DAX 7 generators to complement Boom’s 42-megawatt Superpower aeroderivative turbinesCombined power equipment will support Boom’s 1.21-gigawatt commitment to Crusoe for critical AI data center infrastructure HOUSTON and LONDON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Baker Hughes (NASDAQ: BKR), an energy technology company, announced Tuesday an award to supply 25 BRUSH™ Power Generation electric generators, along with Automatic Voltage Regulators (AVRs) and cubicl ...

MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will release financial results for the fourth quarter and full year 2025 on March 10, 2026. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis we ...

The partnership will expand accessibility to Alberta Health-covered care, providing residents with access to licensed Alberta physicians virtually, from the location of their choice, with no user fees.Rocket Doctor’s platform will be tailored to Lethbridge County residents, supporting a wide range of needs including urgent care, chronic condition management / primary care, and mental health services.This collaboration addresses critical primary and urgent care gaps in rural communities, particularly for res ...

Marine brands again achieve 90%+ customer satisfaction in NMMA’s industry benchmark programChris-Craft adds 2026 Innovation Award for its reimagined Launch 27 EDEN PRAIRIE, Minn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Winnebago Industries (NYSE: WGO), a leading manufacturer of premium outdoor recreation products, today announced that its marine brands, Chris-Craft and Barletta Boats, have once again been recognized with Marine Industry Customer Satisfaction Index (CSI) Awards from the National Marine Manufactur ...

Holders of greater than 99% of the aggregate principal amount of the Existing Notes have already tendered and delivered their consents. Holders of greater than 99% of the aggregate principal amount of the Existing Term Loans have already agreed to participate in the Term Loans Transactions. ST. LOUIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ: ADV) (“Advantage Solutions”), a leading provider of business solutions to consumer goods manufacturers and retailers, today announced the ear ...

MCDONALD, Tenn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Amaero Ltd (ASX:3DA) (OTC: AMROF) (“Amaero” or the “Company”), a leading U.S. domestic producer of high-value refractory and titanium alloy powders for additive and advanced manufacturing of components utilized by the defense, space, and aviation industries, is pleased to advise that it has entered into a scheme implementation deed (“SID”) with Amaero Inc. (a newly-formed Delaware corporation) (“Amaero US HoldCo”) to pursue a re-domiciliation of Amaero and ...

Company strengthens industry-leading compliance program with new per-transaction identity verification procedure, enhancing protections against Crypto ATM fraudATLANTA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bitcoin Depot (NASDAQ: BTM), a U.S.-based Bitcoin ATM (“BTM”) operator and leading fintech company, today announced it has initiated a phased rollout of a new compliance enhancement requiring customers to provide identification for every transaction at its kiosks, strengthening the Company’s safeguards again ...

Core Insights - Artiva Biotherapeutics has appointed Thad Huston as Chief Financial Officer, bringing extensive experience in capital allocation and operational execution to support the company's growth in cell therapies for autoimmune diseases and cancers [1][2]. Company Overview - Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing safe and effective cell therapies for patients with autoimmune diseases and cancers [1][6]. - The company's lead program, AlloNK, is an allogeneic NK cell therapy designed to enhance the efficacy of monoclonal antibodies for B-cell depletion [6]. Leadership Appointment - Thad Huston has over 30 years of global leadership experience in finance, commercial strategy, and operations within the pharmaceuticals and biotechnology sectors [2]. - Huston previously served as CFO and COO at Galapagos, leading the company's transition to an oncology-focused cell therapy organization [2]. Inducement Grant - Artiva's Board of Directors approved an employment inducement grant of 220,000 restricted stock units to Mr. Huston, which will vest over four years [3][4]. - The grant is contingent upon the filing of a registration statement to register the shares under Artiva's 2025 Inducement Plan [4][5]. Clinical Development - AlloNK is currently being evaluated in three clinical trials targeting B-cell driven autoimmune diseases, including rheumatoid arthritis and Sjögren's disease [6]. - The company is preparing to receive feedback from the FDA regarding a potential pivotal trial and plans to share clinical efficacy data in rheumatoid arthritis in the first half of the year [2]. Strategic Positioning - Artiva aims to position itself for sustained growth by leveraging Huston's financial discipline and operational rigor as it approaches key clinical and regulatory milestones [2].